CCL4 and nasopharyngeal carcinoma: To remove the potential confounding factor of subclinical malignancies that might change the circulating MIP-1α and MIP-1β levels, we excluded NPC cases diagnosed within 1 year after baseline blood collection in the nested case–control study.